Clinical Trial Update: Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pomalidomide in combination with obinutuzumab for relapsed/refractory indolent non-Hodgkin lymphoma; the study is not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• Pomalyst (pomalidomide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Indolent Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING